Kilfat Tablet contains Cetilistat 60 mg, an anti-obesity agent designed to aid in weight management by inhibiting gastrointestinal lipases. Cetilistat works by selectively blocking pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This inhibition reduces fat absorption by approximately 30%, leading to decreased caloric intake and promoting weight loss. Kilfat Tablet is indicated for the treatment of obesity, particularly in patients with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² accompanied by obesity-related comorbidities such as type 2 diabetes, hypertension, or dyslipidemia. It is intended to be used as an adjunct to a reduced-calorie diet and increased physical activity. The recommended dosage is one 60 mg tablet taken orally three times daily with each main meal containing fat. Common adverse effects include gastrointestinal symptoms such as oily spotting, flatulence with discharge, fecal urgency, and abdominal discomfort, which are generally mild to moderate and tend to decrease over time. Kilfat Tablet should be used under medical supervision, with monitoring for fat-soluble vitamin deficiencies and potential drug interactions. It is contraindicated in patients with chronic malabsorption syndrome or cholestasis.